Report Overview

Indian Fragile X Syndrome (FXS) Treatment market size stood at around USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period.

India has over 4, 00,000 affected children. If one considers, Fragile X Syndrome (FXS) and its associated disorders, it increases to 40 lakhs. It is a very huge number. FXS is a rare disorder. It is caused by a change in a gene that is inherited at the time of conception. When the gene called the FMR1, found in the X chromosome undergoes a change and does not function properly, it affects brain functions. It causes a wide range of cognitive impairment, from mild learning disabilities to severe intellectual disabilities (ID) that can impact individuals and families in various ways. Children suffering with fragile X syndrome could also show anxiety and hyperactive behavior such as fidgeting or impulsive behavior. These children could also suffer from reduced ability to maintain attention and exhibit difficulty in concentrating on specific tasks. Around one-third of individuals suffering with fragile X syndrome have some symptoms of autism spectrum disorders that disturb communication as well as social interaction. About 15% men and 5% women suffering from fragile X syndrome can experience seizures. These are key factors pushing towards more growth in the Indian fragile X syndrome market.



Market Drivers

Prevalence of fragile X syndrome is rising owing to lack of awareness among people about genetic disorders that result in mutations in DNA. Smoking, consumption of alcohol during pregnancy, and hereditary disorders increase the prevalence of fragile X syndrome. The pipeline of Indian fragile X syndrome market is anticipated to expand rapidly during the forecast period owing to increase in focus of pharmaceuticals & biotechnology companies on conducting research programs to develop effective therapeutic agents for the treatment of the syndrome.